Envestnet Asset Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Envestnet Asset Management’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,872	Closed	-$10.5K	–	4174
2022 Q4	$10.5K	Buy	+11,872	New	+$15.7K	﹤0.01%	3938
2020 Q1	–	Sell	-17,862	Closed	-$60K	–	3186
2019 Q4	$60K	Buy	17,862 +1,827	+11%	+$4.36K	﹤0.01%	3033
2019 Q3	$34K	Sell	16,035 -1,404	-8%	-$3.27K	﹤0.01%	3000
2019 Q2	$47K	Buy	17,439 +2,525	+17%	+$9.09K	﹤0.01%	2992
2019 Q1	$71K	Buy	14,914 +4,316	+41%	+$11.3K	﹤0.01%	2914
2018 Q4	$25K	Buy	+10,598	New	+$34.6K	﹤0.01%	2828

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Envestnet Asset Management's SRNE Position: Q1 2023 in Review

Envestnet Asset Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 11,872 shares — an estimated $10.5K sold.

Envestnet Asset Management first reported a position in SRNE in Q4 2018 and held it in 6 quarters. The position peaked at $71K in Q1 2019. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Envestnet Asset Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Envestnet Asset Management sold 11,872 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $10.5K.
Envestnet Asset Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2018 and held it in 6 quarters.
Envestnet Asset Management's Sorrento Therapeutics, Inc. position peaked at $71K in Q1 2019.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Envestnet Asset Management's 13F filing for Q1 2023, filed 11 May 2023.